A new platform developed by researchers at the University of Texas MD Anderson Cancer Center quickly finds and isolates rare, tumor-reactive immune cells that are especially good at recognizing and attacking cancer cells, even without knowing which tumor targets are recognized by the immune cells. This approach addresses a major bottleneck in immunotherapy development and could accelerate the creation of personalized treatments.
🛡️
We’re checking your connection to prevent automated abuse